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Abstract
Objectives—Polymerase chain reaction (PCR) has been shown to have an excellent sensitivity 
and specificity for the detection of Clostridium difficile infection (CDI). Little is known about risk 
factors for CDI within 14 days of an initial negative test. We sought to determine the 
characteristics among hospitalized patients associated with risk of short-term acquisition of CDI.
Methods—A case-control study was conducted. Cases were patients who converted from PCR 
negative to positive within 14 days. Each case was matched with three controls. Conditional 
logistic regression was used to estimate the association between patient characteristics and CDI.
Results—Of the 30 patients in our study who had a positive PCR within 14 days of a first 
negative PCR (cases), 15 (50%) occurred within 7 days of the initial test. Cases had a higher 
proportion of intravenous vancomycin use in the previous 8 weeks (odds ratio [OR], 3.38; 95% 
confidence interval [CI], 1.34-8.49) and were less likely to have recent antiviral agent use (OR, 
0.30; 95% CI, 0.11-0.83) compared with controls.
Conclusions—In hospitalized patients, treatment with intravenous vancomycin within the prior 
8 weeks of a first negative PCR test for C difficile is a risk factor for short-term risk for hospital-
acquired CDI. Repeat testing guidelines for C difficile PCR should take into consideration patients 
who may be at high risk for short-term acquisition of CDI.
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Clostridium difficile was not identified as the causative bacterial agent for antibiotic-related 
diarrhea until the late 1970s1-3 and is now recognized as the leading cause of infectious 
nosocomial (hospital-acquired) diarrhea.3,4 The median onset of symptomatic infection after 
colonization with toxigenic C difficile spores is typically 2 to 3 days.5 Recently, molecular 
testing has been recognized as an important tool for C difficile infection (CDI) diagnosis, 
with a sensitivity and specificity of 73% to 100% and 91% to 100%, respectively.6 Due to 
the high specificity of the test, most institutions using polymerase chain reaction (PCR) to 
diagnose CDI advocate against repeat testing within 7 days of an initial negative test.7 
Short-term acquisition of CDI, meaning a positive PCR test on repeat testing after an initial 
negative test within 14 days, is rare, but it does occur in 1% to 4% of patients who undergo 
repeat testing, and the specific risk factors are unknown.7-12 Patients with short-term 
acquisition of CDI are exclusively inpatients since they are most likely to undergo expedited 
repeated testing.7,8 Since repeat PCR testing for C difficile is costly, determining which 
patients would likely benefit from repeat testing could be used to guide laboratory 
policies.13
The overall goal of this study was to determine if identifiable patient characteristics would 
improve the efficiency of a short-term repeat testing protocol for detecting C difficile. The 
objectives of this study were to determine the rate of short-term acquisition (within 14 days) 
of CDI after an initial negative PCR in our institution and to determine patient 
characteristics and antibiotic regimens associated with acquisition.
Materials and Methods
This case-control study was conducted at a university-affiliated health care system in a large 
metropolitan area in the Southeast United States. Adult patients (aged ≥18 years) had a feces 
sample ordered in any clinical setting (if the clinician had any concern that the patient may 
have had CDI based on the presence of fever, leukocytosis, abdominal pain, diarrhea, or 
ileus). All PCR tests sent for testing for C difficile from November 2010 to September 2012 
were eligible for the study. From the total pool of PCR tests, those that were repeated within 
14 days were identified. Cases were defined as patients with an initially negative PCR test 
followed by a subsequent positive PCR test within 14 days of the previous negative test. 
Controls were chosen from the same pool of repeat PCR testing but remained negative 
during the entire hospital stay Figure 1.
Cases were matched to three randomly selected controls by (1) days of hospitalization to 
first C difficile PCR test (±1 day) and (2) age (range ±10 years). Two of the cases needed to 
be paired with two controls outside the age range (±15 years). These variables were selected 
for matching because they are established confounders for risk of CDI.14,15
All cases had diarrheal disease indicative of CDI confirmed by chart review and were not 
considered colonized by C difficile. Retrospective chart reviews were performed to obtain 
patient information on baseline demographics, clinical characteristics, and comorbidities 
from the electronic medical record. We chose the following patient characteristics to abstract 
based on the literature, including age,14 immunosuppression (chemotherapy16, 
neutropenia17, human immunodeficiency virus18), recent gastrointestinal (GI) surgery,19 
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tube feeding,20 use of proton pump inhibitors (PPIs),21 and duration of hospitalization.22,23 
Antimicrobial use was collected for the following medication classes (both 8 weeks before 
and 14 days after first negative test): β-lactam, macrolide, quinolone, aminoglycoside, 
trimethoprimsulfamethoxazole, metronidazole, intravenous vancomycin, oral vancomycin, 
antifungal, antiviral (acyclovir prophylaxis), linezolid, tetracycline, clindamycin, aztreonam, 
daptomycin, and an “other” category. Other clinical variables collected included if the 
patient had a GI procedure 8 weeks prior to the first negative test, PPI therapy use within 7 
days prior to the first negative test, chronic steroid use (≥10 mg daily prednisone for ≥3 
months), intensive care unit (ICU) admission within 7 days prior to testing and/or 48 hours 
after testing, and concurrent coinfections (either GI or systemic).
Variables that were collected specifically after the first negative test include ICU admission 
as listed above, antibiotics during the 14-day time period after the first negative test, and 
treatment for CDI. All data were entered into a REDCap electronic database.24
Laboratory Measures
All feces samples sent to the clinical microbiology laboratory for C difficile testing were 
processed according to the manufacturer's instructions for the Xpert C difficile test (Cepheid, 
Sunnyvale, CA), which detects the presence of the toxin B gene by real-time PCR.25
Statistical Analyses
Data were analyzed using SAS version 9.3 (SAS Institute, Cary, NC) and OpenEpi 2.3.1 
(Open Source Epidemiologic Statistics for Public Health, Atlanta, GA). The underlying rate 
for the health care system of short-term acquisition of CDI after a first negative test was 
calculated using the number of new CDI cases divided by the person days of hospitalized 
patients who were tested for C difficile. This calculation assumed that all other individuals in 
the hospital were not tested and did not have CDI. Those at risk included the sum of the 
person days of the cases until their positive PCR and the total hospital days of the 
individuals who had repeat testing but did not become PCR positive. The χ2 test (for 
categorical variables) or Wilcoxon rank-sum test (for continuous variables) was used to 
assess the association between patient characteristics and incident CDI. A two-sided P value 
less than .05 was considered statistically significant. Conditional logistic regression was 
used to estimate the adjusted association (adjusted odds ratios [ORs] and 95% confidence 
intervals [CIs]) between covariates and acquisition of C difficile, controlling for the matched 
patient characteristics (age and days of hospitalization to first PCR test).
Ethical Review
The Emory University Institutional Review Board reviewed the study protocols with 
expedited approval for minimal risk.
Results
During the study period, a total of 12,021 C difficile PCR tests were performed, and of 
those, 9,312 PCR tests were excluded because those patients received only a single test 
(Figure 1). Of the 2,709 tests that remained, 430 PCR tests were further excluded because 
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the repeated testing was performed after a first positive test. Of the 2,279 that had a repeat 
PCR test after a first negative PCR, 1,500 were within 14 days. From these, we identified 60 
PCR tests or 30 cases of patients with short-term CDI acquisition who had an initial negative 
PCR followed by a positive PCR within 14 days. Fifteen (50%) of the 30 cases acquired 
CDI within 7 days of the first negative PCR, which is within the window that repeat testing 
is typically rejected from the laboratory.7 The rate of short-term acquisition of CDI in the 
study population was 142 per 100,000 person years (95% CI, 97-200 per 100,000 person 
years).
The patients’ clinical characteristics are shown in Table 1. In total, 120 patients were 
included (30 cases and 90 controls), 52.5% (63/120) were male, median age was 60 (range, 
25-88) years, and the median hospital stay was 24 (range, 4-143) days. Sixty-one percent 
(73/120) had diarrheal disease during the first PCR test; of the cases, 13 (43.3%) had 
diarrhea before the first test, and 20 (66.6%) had diarrhea before the second test. There were 
no significant differences between cases and controls in patient characteristics and 
comorbidities. Compared with controls, cases were more likely to be male (63.3% vs 
48.9%), have had a recent GI procedure (26.7% vs 13.3%), and were less likely to have 
leukemia (23.3% vs 35.6%), although these differences were not statistically significant.
Table 2 shows antibiotic use. In the 8 weeks prior to the first negative PCR test, cases were 
more likely than controls to be receiving intravenous vancomycin (66.7% vs 38.9%; P = .
009) and less likely to be taking antiviral medication (20.0% vs 44.4%; P = .02). In the 14 
days after the first negative PCR test, cases were more likely than the controls to be taking 
oral vancomycin (16.7% vs 3.3%; P = .01) or metronidazole (33.3% vs 16.7%; P = .05), 
which are the treatments for CDI.23
After adjusting for age and days of hospitalization prior to first PCR, no patient 
characteristics were strongly associated with cases or controls Table 3. In adjusted analysis, 
cases were more likely to have end-stage renal disease (ESRD) (OR, 1.71; 95% CI, 
0.60-4.19) and be patients with a recent GI procedure (OR, 2.41; 95% CI, 0.84-6.88), but the 
detected differences were not statistically significant.
When comparing antibiotic use before the first performed PCR test (Table 3), the odds of 
previous intravenous vancomycin was more common among cases than controls (OR, 3.38; 
95% CI, 1.34-8.49), while the use of acyclovir for prophylaxis was more common among 
the controls (OR, 0.30; 95% CI, 0.11-0.83). When comparing antibiotic use 14 days after the 
first PCR test, the odds of taking metronidazole or oral vancomycin (which are established 
treatments for CDI) were more common among cases.
When combining antibiotic classes Table 4, intravenous vancomycin therapy with a β-
lactam antibiotic in the 8 weeks prior to the first PCR test showed an increased odds in cases 
(OR, 2.72; 95% CI, 1.10-6.72). The same effect was seen when combining intravenous 
vancomycin, a β-lactam, and a quinolone (OR, 2.60; 95% CI, 1.05-6.46). No antibiotic 
combination 14 days after the first test showed statistical significance.
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The rate of short-term acquisition in this study is comparable to the crude incidence rates in 
other studies,26 and the percentage of PCR tests (4.2%) that were initially negative and 
subsequently positive within 14 days is similar to other studies (2.1%-3.4%).7,8,12
In this case-control study of short-term acquisition of CDI among hospitalized patients, we 
found that intravenous vancomycin (within 8 weeks prior to the first PCR-negative test) was 
significantly more common among cases than among controls (OR, 3.38; 95% CI, 
1.34-8.49), even after adjusting for age and length of hospitalization. In addition, we found 
that compared with controls, cases were significantly less likely to have a history of 
acyclovir prophylaxis (OR, 0.30; 95% CI, 0.11-0.83).
The finding that intravenous vancomycin was associated with short-term acquisition of CDI 
could be partially explained by the fact that more cases were highly health care experienced 
and also had substantial underlying comorbidities such as immunosuppression and ESRD. 
This finding has been described before,15 and one study attributed an adjusted OR of 1.9 for 
incident CDI (95% CI, 1.7-2.7) if administered for more than 7 days.27 Intravenous 
vancomycin can be used for surgical prophylaxis, but in this study, it was used in patients 
with culture-directed infections or as empirical treatment for febrile syndromes in 
complicated (immuno-compromised, long-term steroid use, or critically ill) patients (data 
not shown). In this patient population, almost half were in the ICU during their 
hospitalization.
Intravenous vancomycin is not indicated as a therapy for C difficile due to poor GI 
penetration (ie, low concentrations found in feces of patients receiving intravenous 
vancomycin).28 However, intravenous vancomycin is associated with altered microbiota, 
specifically selecting for vancomycin-resistant enterococci.29 While intravenous 
vancomycin may not be in the causal pathway of short-term acquisition of C difficile, it is 
clearly important.
Two recent meta-analyses of antibiotic classes and their risk of incident CDI focused 
exclusively on community-associated CDI30,31; our hospitalized patient cohort is different, 
with almost no patients receiving antimicrobials (such as clindamycin), which are typically 
given on an outpatient basis. Our patients tended to be taking intravenous antibiotics and 
were being exposed to the hospital reservoir of C difficile. Given this finding, the 
assumption was that the increased odds associated with intravenous vancomycin might have 
been a surrogate for poly-antimicrobial use. Previous research demonstrated that antibiotic 
perturbation is necessary for dysbiosis that allows C difficile to causes disease.32,33 
Therefore, chronic comorbidities that may require frequent antibiotic use (and, 
consequently, hospital exposure to C difficile spores) or that result in immune compromise 
may place individuals at increased risk for short-term acquisition of CDI. The strong 
association with intravenous vancomycin reported in our study may be a surrogate for 
individuals who are more chronically ill.34
We think that the estimated protective effect of acyclovir was biased due to a higher 
proportion of patients with hematologic malignancy in the control population. Our cohort of 
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750 individuals from which we drew the cases and controls were hospitalized for lengthy 
periods (such as hematopoietic stem cell transplant patients), and we randomly oversampled 
a group that used acyclovir for prophylaxis.
Our study was subject to limitations. First, systematic error due to residual confounding may 
have occurred due to the limited covariates from study patients that were available for 
collection during chart review. Second, chart reviews performed could not determine the 
exact indications for previous antibiotic use. If the indication for antibiotic use was causally 
related to short-term CDI risk and associated with other patient covariates used in this study, 
confounding by indication could result in biased estimates.35 However, we do not believe 
this to be a major problem because most of the time, antibiotics were used for culture-
directed infections or as empirical use in febrile syndromes in complicated patients. Another 
limitation is that we were unable to determine if patients had previously had CDI. Our 
institution used a different test to diagnose CDI (enzyme immunoassay alone) before 
November 2010, so it would be very difficult to compare previous diagnosed cases with our 
current highly sensitive molecular method.36 Third, the study's laboratory policy is to 
automatically reject feces submitted within 7 days of an initial negative test unless the 
practitioner requests a test to be performed again, which means we could have missed some 
cases/controls due to the clinician not being concerned enough to request a repeat test.
The purpose of this study was to delineate a subgroup of patients who would assist 
laboratorians in determining a clinical history that may be associated with a short-term risk 
of CDI. Given that short-term acquisition while in the hospital is relatively rare, this group 
of patients has not been studied to determine if there is a characteristic associated with CDI. 
While the standard practice in the clinical microbiology laboratory is to reject feces samples 
that are sent for C difficile PCR within 7 days,7 this interval is not derived from biologic 
studies that show that C difficile can be detected within 3 to 7 days of infection.5 Although it 
is clear that most patients do not need repeated C difficile testing within 14 days, there are 
still individuals who test positive within this time frame, and this is an important diagnosis 
to make from an individual's standpoint.3
In conclusion, intravenous vancomycin use within the 8 weeks prior was predictive of short-
term acquisition of C difficile in hospitalized patients. The practical implications for this in 
terms of repeated testing may include eliciting this antibiotic history when clinicians request 
repeat testing earlier than 7 days in a hospitalized patient.
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Cases and controls selected from the total cohort of polymerase chain reaction (PCR) tests 
performed from November 2010 to September 2012. n represents the number of PCR tests 
(not patients), and % represents the percentage in comparison to the total cohort of PCR 
tests (100% cohort = 12,021 PCR tests).
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Table 1
Baseline Characteristics of Cases and Controlsa
Characteristic Cases (n = 30) Controls (n = 90) P Value
Days to first test,b median (IQR) 7.8 (5.8) 7.8 (5.7) .95
Age, median y (IQR) 58.8 (13.5) 58.6 (13.5) .98
Sex
    Female 11 (36.7) 46 (51.1) .17
    Male 19 (63.3) 44 (48.9)
Hospital stay, median d (IQR) 27.0 (18.0) 22.5 (18.0) .39
Death (all causes) 5 (16.7) 9 (10.0) .33
Intensive care unit stayc 11 (36.7) 43 (47.8) .29
Diabetes mellitusd 7 (23.3) 22 (24.4) .90
Coinfectione 18 (60.0) 47 (52.2) .46
Proton pump inhibitor 26 (86.7) 76 (84.4) .77
Recent GI proceduref 8 (26.7) 12 (13.3) .09
End-stage renal disease 6 (20.0) 11 (12.2) .29
Leukemia 7 (23.3) 32 (35.6) .22
Solid tumor 5 (16.7) 9 (10.0) .33
Chemotherapyg 10 (33.3) 31 (34.4) .91
Stem cell transplant 1 (3.3) 1 (1.1) .41
Solid organ transplant 2 (6.7) 9 (10.0) .58
GI, gastrointestinal; IQR, interquartile range.
aValues are presented as number (%) unless otherwise indicated.
b
Days of hospitalization prior to first Clostridium difficile polymerase chain reaction (PCR) test.
c
Intensive care unit stay within 7 days before or 48 hours after first PCR test.
d
Defined as HbA1c of more than 6.5%.
e
Infection of any type and any source at the time of PCR testing.
fGI procedure of any type within 8 weeks prior to first PCR test.
g
Received chemotherapy for malignancy within the past 8 weeks.
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Table 2
Antibiotics Used 8 Weeks Prior to First PCR Testa
No. (%)
Antibiotic Cases (n = 30) Controls (n = 90) P Valueb
β-Lactam 22 (73.3) 50 (55.6) .09
Quinolone 14 (46.7) 40 (44.4) .83
Aminoglycoside 1 (3.3) 6 (6.7) .50
Metronidazole (PO/IV) 2 (6.7) 9 (10.0) .58
Vancomycin IV 20 (66.7) 35 (38.9) .009
Acyclovir prophylaxis 6 (20.0) 40 (44.4) .02
Antibiotic use 14 days after first PCR test
    β-Lactam 19 (63.3) 62 (68.9) .58
    Quinolone 12 (40.0) 33 (36.7) .75
    Aminoglycoside 3 (10.0) 6 (6.7) .55
    Metronidazole (PO/IV) 10 (33.3) 15 (16.7) .05
    Vancomycin IV 9 (30.0) 43 (47.8) .09
    Vancomycin PO 5 (16.7) 3 (3.3) .01
    Acyclovir prophylaxis 8 (26.7) 37 (41.1) .16
IV, intravenous; PCR, polymerase chain reaction; PO, oral.
aOther antibiotics analyzed but not shown (as total number of patients receiving them ≤5) were macrolides, trimethoprim-sulfamethoxazole, 
antifungals, linezolid, tetracyclines, clindamycin, aztreonam daptomycin, and “others” (carbapenem, dapsone, meropenem, nitrofurantoin, and 
tigecycline). None was statistically significant.
b
Bold signifies statistical significance, two-sided P < .05.
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Table 3
Conditional Logistic Regression Matched Odds Ratios for Patient Characteristics and Antibiotic Use 
Associated With Short-Term Acquisition of Clostridium difficilea
Characteristic OR (95% CI)b
Male sex 1.87 (0.76-4.18)
Death (all causes) 1.85 (0.54-6.28)
Intensive care unit stayc 0.59 (0.24-1.45)
Diabetes mellitusd 0.94 (0.35-2.47)
Coinfectione 1.49 (0.58-3.82)
Proton pump inhibitor 1.18 (0.37-3.73)
Recent GI proceduref 2.41 (0.84-6.88)
End-stage renal disease 1.72 (0.60-4.19)
Leukemia 0.49 (0.17-1.38)
Solid tumor 1.85 (0.54-6.28)
Chemotherapyg 0.94 (0.37-2.40)
Stem cell transplant 3.00 (0.19-47.96)
Solid organ transplant 0.67 (0.14-3.09)
Antibiotic use 8 weeks prior to first PCR testh
    β-Lactam 2.35 (0.91-6.07)
    Quinolone 1.10 (0.47-2.59)
    Aminoglycoside 0.50 (0.06-4.15)
    Metronidazole 0.67 (0.14-3.09)
    Vancomycin IV 3.38 (1.34-8.49)
    Acyclovir prophylaxis 0.30 (0.11-0.83)
Antibiotic use 14 days after first PCR testh
    β-Lactam 0.81 (0.36-1.81)
    Quinolone 1.18 (0.47-2.98)
    Aminoglycoside 1.50 (0.38-6.00)
    Metronidazole 2.39 (0.95-6.06)
    Vancomycin IV 0.47 (0.19-1.16)
    Vancomycin PO 6.63 (1.27-34.74)
    Acyclovir prophylaxis 0.51 (0.20-1.29)
CI, confidence interval; GI, gastrointestinal; IV, intravenous; OR, odds ratio; PCR, polymerase chain reaction; PO, oral.
aOR matched on age and days to first PCR test.
b
Bold signifies statistical significance.
c
Intensive care unit stay within 7 days before or 48 hours after first PCR test.
d
Defined as HbA1c of more than 6.5%.
e
Infection of any type and any source at the time of PCR testing.
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fGI procedure of any type within 8 weeks prior to first PCR test.
g
Received chemotherapy for malignancy within the past 8 weeks.
hOther antibiotics analyzed but not shown were macrolides, trimethoprim-sulfamethoxazole, antifungals, linezolid, tetracyclines, clindamycin, 
aztreonam, daptomycin, and “others” (carbapenem, dapsone, meropenem, nitrofurantoin, and tigecycline). None was statistically significant.
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Table 4
Matched Odds Ratio for Combined Antibiotic Classes Associated With Short-Term Acquisition of 
Clostridium difficilea
Antibiotic OR (95% CI)b
Antibiotic class administered 8 weeks prior to first test
    β-Lactam 2.35 (0.91-6.07)
    Quinolone 1.10 (0.47-2.59)
    Vancomycin IV 3.38 (1.34-8.49)
    β-Lactam + vancomycin IV 2.72 (1.10-6.72)
    β-Lactam + vancomycin IV + quinolone 2.60 (1.05-6.46)
Antibiotic class administered 14 days after first test
    β-Lactam 0.81 (0.36-1.81)
    Quinolone 1.18 (0.47-2.98)
    Vancomycin IV 0.47 (0.19-1.16)
    β-Lactam + vancomycin IV 0.49 (0.20-1.22)
    β-Lactam + vancomycin IV + quinolone 0.78 (0.35-1.73)
CI, confidence interval; IV, intravenous; OR, odds ratio.
aOR matched on age and days to first test.
b
Bold signifies statistical significance.
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